Industry Network Interpharma is the umbrella association for 24 research-based pharma companies in Switzerland, including global giants like Roche, Novartis, J&J, and Pfizer. This presents a centralized opportunity to access multiple potential buyers and decision-makers through a single engagement strategy, leveraging the consortium’s influence to introduce new solutions that benefit the Swiss pharmaceutical ecosystem.

Innovation Focus The organization prioritizes innovation, supporting pharma research, development, and production while promoting new technologies and intellectual property protection. Sales opportunities lie in advanced manufacturing, analytics, supply chain resilience, and digital health solutions that enhance R&D productivity and protect IP across member companies.

COVID-19 Portfolio Past and ongoing emphasis on next-generation COVID-19 vaccines and adjuvanted protein vaccines, along with collaborations on CureVac, indicates a continued appetite for vaccine platforms, adjuvants, and scalable production capabilities. Opportunities exist for partners offering vaccine technology, adjuvants, manufacturing scale-up, and regulatory-compliant support services.

Public Policy Engagement Interpharma actively participates in national health policy and public communications, aiming to shape a favorable environment for pharma innovation. This suggests sales potential for services that support policy analytics, governmental affairs, and stakeholder outreach, as well as solutions that demonstrate value to health technology assessment bodies.

Digital & Data Readiness The mix of tech tools (Drupal, WordPress, Shopify, Microsoft 365) alongside a map of member locations signals a readiness for digital-enabled collaboration and data services. Potential sales avenues include cloud-based collaboration platforms, data integration, content management, and digital engagement tools tailored for a multi-member industry association.